Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Website: maxcyte.com


  • Good financial results growth rate 71.9% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (10.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -15.7% (LTM)
  • Share price is 0.0% higher than minimum and 79.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: MXCT
Share price, USD:  (0.0%)1.13
year average price 2.0248  


year start price 4.1700 2025-02-14

max close price 4.1700 2025-02-14

min close price 1.1300 2026-01-27

current price 1.1300 2026-02-13
Common stocks: 101 702 664

Dividend Yield:  0.0%
EV / Sales: 1.5x
Margin (EBITDA LTM / Revenue): -119.1%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 115
Net Debt ($m): -10
EV (Enterprise Value): 105
EBITDA LTM (млн $): -81
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-12seekingalpha.com

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

2025-10-08globenewswire.com

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

2025-10-06globenewswire.com

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

2025-09-22globenewswire.com

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

2025-08-07seekingalpha.com

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

2025-08-06zacks.com

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

2025-07-09globenewswire.com

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

2025-07-01businesswire.com

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

2025-06-11globenewswire.com

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

2025-05-10seekingalpha.com

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-06 2024-11-06 2024-08-06 2024-05-07 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-13 16:34:49 2025-08-06 16:46:55 2025-03-11 17:05:30 2024-11-06 16:55:29 2024-08-06 16:55:36 2024-05-07 17:00:41 2024-03-12 17:00:43 2023-11-08 17:12:29 2023-08-09 16:55:49 2023-05-10 17:03:57 2023-03-15 17:01:01 2022-11-09 17:01:22 2022-03-22 17:16:08 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 7M 9M 39M 8M 10M 11M 41M 8M 9M 9M 44M 11M 34M 26M
costOfRevenue 516 000 2M 7M 2M 3M 2M 5M 793 400 1M 999 800 5M 1M 4M 3M
grossProfit 6M 7M 32M 6M 8M 9M 37M 7M 8M 8M 39M 9M 30M 23M
grossProfitRatio 0.924 0.821 0.764 0.758 0.782 0.901 0.848 0.883 0.871
researchAndDevelopmentExpenses 5M 6M 22M 5M 6M 7M 24M 6M 6M 6M 20M 5M 15M 18M
generalAndAdministrativeExpenses 6M 8M 30M 8M 8M 7M 30M 7M 8M 7M 26M 6M 19M 7M
sellingAndMarketingExpenses 4M 6M 27M 6M 7M 7M 27M 7M 6M 6M 19M 5M 13M 8M
sellingGeneralAndAdministrativeExpenses 10M 14M 56M 14M 14M 14M 57M 14M 14M 14M 44M 11M 32M 16M
otherExpenses 2M 1M 4M 1M 1M 0 4M 239M 0 912 200 3M 709 800 1M 1M
operatingExpenses 17M 21M 83M 20M 20M 21M 85M 21M 21M 21M 67M 17M 48M 34M
costAndExpenses 17M 23M 90M 22M 22M 24M 90M 22M 22M 22M 72M 18M 52M 37M
interestIncome 2M 2M 10M 2M 3M 3M 10M 3M 3M 2M 4M 1M 150 800 65 900
interestExpense 0 0 0 0 0 0 0 0 0 -2M 126 900 116 000 1M 825 600
depreciationAndAmortization 848 000 1M 5M 1M 1M 1M 4M 1M 1M 961 700 3M 2M 1M 1M
ebitda -12M -13M -46M -13M -11M -11M -44M -13M -12M -12M -25M -6M -17M -10M
ebitdaratio -1.694 -1.52 -1.591 -1.041 -0.981 -1.608 -1.332 -1.424 -0.527
operatingIncome -11M -14M -51M -14M -12M -12M -48M -14M -13M -13M -27M -8M -18M -11M
operatingIncomeRatio -1.548 -1.672 -1.721 -1.145 -1.079 -1.743 -1.446 -1.536 -0.725
totalOtherIncomeExpensesNet -2M 2M 10M 2M 3M 3M 10M 1 908M 1 584M 2M 4M 1M -893 600 -759 700
incomeBeforeTax -12M -12M -41M -12M -9M -10M -38M -11M -11M -11M -24M -6M -19M -12M
incomeBeforeTaxRatio -1.818 -1.453 -1.416 -0.899 -0.84 -1.406 -1.162 -1.269 -0.605
incomeTaxExpense 0 0 0 0 0 1M 0 1 905M 1 582M -2M 0 -1M 0 0
netIncome -12M -12M -41M -12M -9M -10M -38M -11M -11M -9M -24M -5M -19M -12M
netIncomeRatio -1.818 -1.453 -1.416 -0.899 -0.84 -1.406 -1.162 -1.001 -0.484
eps -0.12 -0.12 -0.39 -0.11 -0.09 -0.092 -0.37 -0.11 -0.1 -0.084 -0.19 -0.051 -0.22 -0.18
epsdiluted -0.12 -0.12 -0.11 -0.09 -0.092 -0.11 -0.1 -0.084 -0.051
weightedAverageShsOut 106M 106M 105M 105M 105M 104M 103M 103M 103M 103M 102M 102M 91M 69M
weightedAverageShsOutDil 106M 106M 105M 105M 105M 104M 103M 103M 103M 103M 102M 102M 91M 69M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-11 2024-03-12 2023-03-15 2022-03-22 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 10M 10M 4M -893 600 -759 700
ebit -51M -48M -27M -18M -11M
nonOperatingIncomeExcludingInterest 0 0 0 -150 800 -65 900
netIncomeFromContinuingOperations -41M -38M -24M -19M -12M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -41M -38M -24M -19M -12M
epsDiluted -0.39 -0.37 -0.19 -0.22 -0.18

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-06 2024-11-06 2024-08-06 2024-05-07 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-13 16:34:49 2025-08-06 16:46:55 2025-03-11 17:05:30 2024-11-06 16:55:29 2024-08-06 16:55:36 2024-05-07 17:00:41 2024-03-12 17:00:43 2023-11-08 17:12:29 2023-08-09 16:55:49 2023-05-10 17:03:57 2023-03-15 17:01:01 2022-11-09 17:01:22 2022-03-22 17:16:08 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 13M 15M 28M 37M 38M 22M 47M 49M 55M 38M 11M 43M 48M 19M
shortTermInvestments 93M 111M 127M 117M 120M 135M 122M 141M 162M 187M 216M 190M 207M 16M
cashAndShortTermInvestments 106M 127M 154M 154M 157M 158M 168M 190M 216M 225M 227M 233M 255M 35M
netReceivables 8M 6M 5M 5M 5M 6M 6M 8M 8M 9M 11M 8M 7M 5M
inventory 8M 8M 9M 10M 11M 12M 12M 13M 11M 10M 9M 8M 5M 4M
otherCurrentAssets 3M 3M 4M 4M 3M 3M 4M 3M 2M 2M 2M 4M 0 0
totalCurrentAssets 125M 143M 172M 173M 176M 179M 190M 214M 237M 246M 252M 252M 270M 45M
propertyPlantEquipmentNet 30M 31M 30M 32M 33M 34M 35M 33M 34M 35M 34M 33M 13M 6M
goodwill 4M 4M 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 667 000 638 000 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 4M 4M 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 52M 39M 36M 43M 42M 45M 43M 18M 161 391M 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 3M 2M 1M 640 000 295 000 388 000 619 400 -161 390M 399 300 809 000 1M 316 700 33 900
totalNonCurrentAssets 89M 77M 68M 76M 76M 79M 78M 52M 35M 35M 34M 34M 14M 7M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 213M 220M 239M 249M 251M 258M 268M 267M 271M 282M 287M 286M 284M 52M
accountPayables 1M 1M 1M 2M 953 000 2M 743 000 446 600 2M 4M 292 000 2M 2M 890 200
shortTermDebt 1M 1M 864 000 907 000 2M 825 000 0 698 700 498 600 475 200 0 152 200 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 5M 3M 5M 7M 3M 4M 5M 6M 5M 6M 0 6M 7M 5M
otherCurrentLiabilities 8M 6M 8M 8M 5M 7M 0 10M 6M 7M 7M 8M 0 0
totalCurrentLiabilities 16M 12M 16M 18M 12M 13M 18M 17M 13M 17M 15M 17M 16M 12M
longTermDebt 17M 17M 0 17M 18M 18M 0 15M 16M 16M 0 15M 0 5M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 344 600 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 252 000 273 000 274 000 277 000 310 000 279 000 283 000 1M 1M 1M 1M 7M 450 200 646 600
totalNonCurrentLiabilities 17M 17M 17M 18M 18M 18M 18M 17M 17M 17M 17M 15M 6M 7M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 18M 19M 17M 18M 19M 18M 19M 16M 16M 16M 16M 15M 6M 2M
totalLiabilities 33M 29M 33M 35M 30M 32M 36M 33M 30M 34M 33M 32M 21M 19M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 773 800
retainedEarnings -252M -239M -217M -206M -195M -185M -176M -171M -159M -149M -138M -133M -114M -95M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 0 -0 0 0 0
othertotalStockholdersEquity 431M 429M 419M 415M 411M 403M 399M 396M 386M
totalStockholdersEquity 180M 191M 206M 213M 221M 226M 232M 233M 241M 248M 254M 254M 263M 33M
totalEquity 180M 191M 206M 213M 221M 226M 232M 233M 241M 248M 254M 254M 263M 33M
totalLiabilitiesAndStockholdersEquity 213M 220M 249M 251M 258M 267M 271M 282M 286M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 213M 220M 239M 249M 251M 258M 268M 267M 271M 282M 287M 286M 284M 52M
totalInvestments 145M 150M 162M 160M 162M 180M 165M 159 499M 161 552M 187M 216M 190M 207M 16M
totalDebt 18M 19M 18M 18M 19M 19M 19M 16M 16M 16M 16M 15M 6M 7M
netDebt 5M 3M -10M -19M -19M -4M -28M -33M -38M -22M 5M -28M -42M -12M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-11 2024-03-12 2023-03-15 2022-03-22 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 5M 6M 11M 7M 5M
otherReceivables 0 0 0 0 0
prepaids 0 0 3M 3M 1M
totalPayables 1M 743 000 292 000 2M 890 200
otherPayables 0 0 0 0 0
accruedExpenses 0 11M 8M 7M 5M
capitalLeaseObligationsCurrent 0 774 000 157 000 527 200 672 600
capitalLeaseObligationsNonCurrent 17M 18M 16M 5M 1M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 407M 391M 376M 128M
otherTotalStockholdersEquity 422M 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT MXCT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-06 2024-11-06 2024-08-06 2024-05-07 2023-11-08 2023-08-09 2023-05-10 2022-11-09
acceptedDate 2025-11-13 16:34:49 2025-08-06 16:46:55 2025-03-11 17:05:30 2024-11-06 16:55:29 2024-08-06 16:55:36 2024-05-07 17:00:41 2024-03-12 17:00:43 2023-11-08 17:12:29 2023-08-09 16:55:49 2023-05-10 17:03:57 2023-03-15 17:01:01 2022-11-09 17:01:22 2022-03-22 17:16:08 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -12M -12M -41M -12M -9M -10M -38M -11M -11M -11M -24M -6M -19M -12M
depreciationAndAmortization 1M 1M 4M 1M 1M 1M 5M 1M 1M 961 700 3M 743 300 1M 1M
deferredIncomeTax 0 0 0 0 0 0 0 -1M -2M 0 0 0 0 0
stockBasedCompensation 0 0 0 3M 4M 3M 14M 4M 4M 3M 0 3M 8M 2M
changeInWorkingCapital 2M -2M -751 000 2M 1M -3M 4M -202 400 -3M 4M -3M -3M -2M -858 200
accountsReceivables -3M -238 000 1M 21 000 2M -343 000 7M -549 700 1M 4M -7M -300 300 -2M -2M
inventory -107 000 223 000 1M 1000 664 000 169 000 -5M -2M -835 700 -2M -3M -241 200 -1M -890 600
accountsPayables 2M 249 000 -2M 0 -211 000 -3M 3M 999 900 -2M 1M -149 700 216 200 2M 391 000
otherWorkingCapital 3M -2M -1M 2M -910 000 22 000 -2M 893 300 -1M 235 300 7M -2M -624 700 1M
otherNonCashItems 2M 3M 10M 505 000 2M 7M -6M 14 200 49 000 -2M 9M -813 200 664 600 373 000
netCashProvidedByOperatingActivities -7M -10M -28M -4M -5M -11M -22M -8M -10M -4M -15M -6M -11M -9M
investmentsInPropertyPlantAndEquipment -300 000 -584 000 -2M -406 000 -294 000 -804 000 -4M -720 200 -507 000 -2M -18M -3M -4M -2M
acquisitionsNet 0 0 0 0 0 0 0 -4M -27M 0 0 0 0 0
purchasesOfInvestments -35M -29M -151M -39M -31M -48M -255M -81M -47M -58M -291M -82M -269M -23M
salesMaturitiesOfInvestments 40M 31M 159M 43M 51M 34M 314M 84M 74M 89M 285M 25M 78M 8M
otherInvestingActivites 0 0 0 20M -14M 4M 27M 9100 0
netCashUsedForInvestingActivites 5M 2M 4M 19M -14M 3M 27M 30M -61M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 14 000 154 000 -1M 713 000 703 000 36 700 156 700 1 457M 0
commonStockRepurchased 0 0 0 265 000 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 228 000 713 000 703 000 36 700 0 -1 455M 444 400
netCashUsedProvidedByFinancingActivities 14 000 154 000 228 000 713 000 703 000 36 700 156 700 1M 444 400
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -2M -8M -19M -555 000 15M -24M 35M -5M 17M 27M -37M -66M 29M 4M
cashAtEndOfPeriod 13M 15M 28M 37M 38M 22M 47M 49M 55M 38M 11M 43M 48M 19M
cashAtBeginningOfPeriod 15M 23M 47M 38M 22M 47M 11M 55M 38M 11M 48M 109M 19M 15M
operatingCashFlow -7M -10M -28M -4M -5M -11M -22M -8M -10M -4M -15M -6M -11M -9M
capitalExpenditure -300 000 -584 000 -2M -406 000 -294 000 -804 000 -4M -720 200 -507 000 -2M -18M -3M -4M -2M
freeCashFlow -8M -10M -29M -5M -5M -11M -25M -9M -11M -6M -33M -9M -15M -11M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-11 2024-03-12 2023-03-15 2022-03-22 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 9000 0 4600 0
netCashProvidedByInvestingActivities 7M 55M -25M -195M -17M
netDebtIssuance 0 0 0 -5M -63 700
longTermNetDebtIssuance 0 0 0 -5M -63 700
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 2M 269 000 3M 236M 29M
netCommonStockIssuance 2M 269 000 3M 236M 29M
commonStockIssuance 2M 269 000 3M 236M 29M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 2M 0 4M 401 000
netCashProvidedByFinancingActivities 2M 2M 3M 235M 29M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 420 900 421 400

Earning call transcript

2025 q3
2025-11-12 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-10 ET (fiscal 2025 q1)
2024 q4
2025-03-11 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-07 ET (fiscal 2024 q2)
2024 q1
2024-05-11 ET (fiscal 2024 q1)
2023 q4
2024-03-12 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-12 ET (fiscal 2023 q1)
2022 q4
2023-03-15 ET (fiscal 2022 q4)
2022 q3
2022-11-12 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-12 21:45 ET
MaxCyte, Inc. published news for 2025 q4
SEC form 8
2026-01-12 21:45 ET
MaxCyte, Inc. published news for 2025 q4
SEC form 10
2025-11-13 21:34 ET
MaxCyte, Inc. reported for 2025 q3
SEC form 8
2025-11-12 21:13 ET
MaxCyte, Inc. published news for 2025 q3
SEC form 8
2025-11-12 21:13 ET
MaxCyte, Inc. reported for 2025 q3
SEC form 8
2025-11-12 21:13 ET
MaxCyte, Inc. published news for 2025 q3
SEC form 8
2025-11-05 22:24 ET
MaxCyte, Inc. published news for 2025 q3
SEC form 8
2025-11-05 22:24 ET
MaxCyte, Inc. reported for 2025 q3
SEC form 8
2025-09-22 20:39 ET
MaxCyte, Inc. published news for 2025 q2
SEC form 8
2025-09-22 20:39 ET
MaxCyte, Inc. published news for 2025 q2
SEC form 10
2025-08-06 20:46 ET
MaxCyte, Inc. reported for 2025 q2
SEC form 8
2025-08-06 20:13 ET
MaxCyte, Inc. published news for 2025 q2
SEC form 8
2025-08-06 20:13 ET
MaxCyte, Inc. reported for 2025 q2
SEC form 8
2025-08-06 20:13 ET
MaxCyte, Inc. published news for 2025 q2
SEC form 8
2025-06-25 20:40 ET
MaxCyte, Inc. published news for 2025 q1
SEC form 10
2025-05-08 21:04 ET
MaxCyte, Inc. reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
MaxCyte, Inc. reported for 2025 q1
SEC form 8
2025-05-07 20:14 ET
MaxCyte, Inc. published news for 2025 q1
SEC form 8
2025-05-07 20:14 ET
MaxCyte, Inc. reported for 2025 q1
SEC form 8
2025-05-07 20:14 ET
MaxCyte, Inc. published news for 2025 q1
SEC form 10
2025-03-11 17:05 ET
MaxCyte, Inc. reported for 2024 q4
SEC form 8
2025-03-11 16:15 ET
MaxCyte, Inc. published news for 2024 q4
SEC form 8
2025-03-11 16:15 ET
MaxCyte, Inc. reported for 2024 q4
SEC form 8
2025-03-11 16:15 ET
MaxCyte, Inc. published news for 2024 q4
SEC form 10
2025-03-11 00:00 ET
MaxCyte, Inc. reported for 2024 q4
SEC form 8
2025-01-30 12:30 ET
MaxCyte, Inc. published news for 2024 q4
SEC form 8
2025-01-30 12:30 ET
MaxCyte, Inc. published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
MaxCyte, Inc. published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
MaxCyte, Inc. published news for 2024 q4
SEC form 10
2024-11-06 16:55 ET
MaxCyte, Inc. reported for 2024 q3
SEC form 8
2024-11-06 16:22 ET
MaxCyte, Inc. published news for 2024 q3
SEC form 8
2024-11-06 16:22 ET
MaxCyte, Inc. reported for 2024 q3
SEC form 8
2024-11-06 16:22 ET
MaxCyte, Inc. published news for 2024 q3
SEC form 10
2024-08-06 16:55 ET
MaxCyte, Inc. reported for 2024 q2
SEC form 8
2024-08-06 16:13 ET
MaxCyte, Inc. published news for 2024 q2
SEC form 8
2024-08-06 16:13 ET
MaxCyte, Inc. reported for 2024 q2
SEC form 8
2024-08-06 16:13 ET
MaxCyte, Inc. published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
MaxCyte, Inc. reported for 2024 q2
SEC form 10
2024-05-07 17:00 ET
MaxCyte, Inc. reported for 2024 q1
SEC form 8
2024-05-07 16:14 ET
MaxCyte, Inc. published news for 2024 q1
SEC form 8
2024-05-07 16:14 ET
MaxCyte, Inc. reported for 2024 q1
SEC form 8
2024-05-07 16:14 ET
MaxCyte, Inc. published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
MaxCyte, Inc. reported for 2024 q1
SEC form 10
2024-03-12 17:00 ET
MaxCyte, Inc. reported for 2023 q4
SEC form 8
2024-03-12 16:10 ET
MaxCyte, Inc. published news for 2023 q4
SEC form 8
2024-03-12 16:10 ET
MaxCyte, Inc. reported for 2023 q4
SEC form 10
2024-03-12 00:00 ET
MaxCyte, Inc. reported for 2023 q4
SEC form 8
2024-03-05 00:00 ET
MaxCyte, Inc. published news for 2023 q4
SEC form 8
2024-03-05 00:00 ET
MaxCyte, Inc. published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
MaxCyte, Inc. published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
MaxCyte, Inc. published news for 2023 q4
SEC form 10
2023-11-08 17:12 ET
MaxCyte, Inc. reported for 2023 q3
SEC form 8
2023-11-08 16:12 ET
MaxCyte, Inc. reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
MaxCyte, Inc. reported for 2023 q3
SEC form 8
2023-10-04 00:00 ET
MaxCyte, Inc. published news for 2023 q3
SEC form 10
2023-08-09 16:55 ET
MaxCyte, Inc. reported for 2023 q2
SEC form 6
2023-08-09 16:16 ET
MaxCyte, Inc. reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
MaxCyte, Inc. reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
MaxCyte, Inc. reported for 2023 q2
SEC form 6
2023-06-23 09:27 ET
MaxCyte, Inc. published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
MaxCyte, Inc. reported for 2023 q1
SEC form 8
2023-05-10 00:00 ET
MaxCyte, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:22 ET
MaxCyte, Inc. published news for 2023 q1
SEC form 6
2023-03-28 09:40 ET
MaxCyte, Inc. published news for 2022 q4
SEC form 10
2023-03-15 17:01 ET
MaxCyte, Inc. reported for 2022 q4
SEC form 6
2023-03-15 16:15 ET
MaxCyte, Inc. reported for 2022 q4
SEC form 10
2023-03-15 00:00 ET
MaxCyte, Inc. reported for 2022 q4
SEC form 8
2023-03-15 00:00 ET
MaxCyte, Inc. reported for 2022 q4
SEC form 6
2023-03-06 17:04 ET
MaxCyte, Inc. published news for 2022 q4
SEC form 8
2023-03-06 00:00 ET
MaxCyte, Inc. published news for 2022 q4
SEC form 6
2022-12-01 08:30 ET
MaxCyte, Inc. published news for 2022 q3
SEC form 10
2022-11-09 17:01 ET
MaxCyte, Inc. reported for 2022 q3
SEC form 6
2022-11-09 16:15 ET
MaxCyte, Inc. reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
MaxCyte, Inc. reported for 2022 q3
SEC form 8
2022-11-09 00:00 ET
MaxCyte, Inc. reported for 2022 q3
SEC form 10
2022-08-10 17:03 ET
MaxCyte, Inc. reported for 2022 q2
SEC form 6
2022-08-10 16:15 ET
MaxCyte, Inc. published news for 2022 q2
SEC form 10
2022-08-10 00:00 ET
MaxCyte, Inc. reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
MaxCyte, Inc. reported for 2022 q2
SEC form 6
2022-06-30 16:44 ET
MaxCyte, Inc. published news for 2022 q1
SEC form 6
2022-05-26 16:35 ET
MaxCyte, Inc. published news for 2022 q1
SEC form 10
2022-05-09 17:00 ET
MaxCyte, Inc. reported for 2022 q1
SEC form 6
2022-05-09 16:15 ET
MaxCyte, Inc. published news for 2022 q1
SEC form 10
2022-05-09 00:00 ET
MaxCyte, Inc. reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
MaxCyte, Inc. reported for 2022 q1
SEC form 6
2022-04-29 16:27 ET
MaxCyte, Inc. published news for 2022 q1
SEC form 6
2022-04-12 16:26 ET
MaxCyte, Inc. published news for 2022 q1
SEC form 8
2022-04-12 00:00 ET
MaxCyte, Inc. published news for 2022 q1
SEC form 10
2022-03-22 17:16 ET
MaxCyte, Inc. published news for 2021 q4
SEC form 6
2022-03-22 16:15 ET
MaxCyte, Inc. published news for 2021 q4
SEC form 10
2022-03-22 00:00 ET
MaxCyte, Inc. published news for 2021 q4
SEC form 8
2022-03-22 00:00 ET
MaxCyte, Inc. published news for 2021 q4
SEC form 6
2022-01-24 17:05 ET
MaxCyte, Inc. published news for 2021 q4
SEC form 8
2022-01-24 00:00 ET
MaxCyte, Inc. published news for 2021 q4
SEC form 10
2021-11-10 16:51 ET
MaxCyte, Inc. published news for 2021 q3
SEC form 6
2021-11-10 16:15 ET
MaxCyte, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
MaxCyte, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
MaxCyte, Inc. published news for 2021 q3
SEC form 6
2021-11-02 16:30 ET
MaxCyte, Inc. published news for 2021 q3
SEC form 6
2021-10-01 08:36 ET
MaxCyte, Inc. published news for 2021 q3
SEC form 6
2021-10-01 07:00 ET
MaxCyte, Inc. published news for 2021 q3
SEC form 6
2021-09-17 16:34 ET
MaxCyte, Inc. published news for 2021 q2
SEC form 8
2021-09-17 00:00 ET
MaxCyte, Inc. published news for 2021 q2
SEC form 10
2021-09-13 16:34 ET
MaxCyte, Inc. published news for 2021 q2
SEC form 10
2021-09-13 00:00 ET
MaxCyte, Inc. published news for 2021 q2
SEC form 6
2021-08-04 16:06 ET
MaxCyte, Inc. published news for 2021 q2